NASH患者肝巨噬细胞在肝纤维化形成过程中的作用及其临床转化研究进展*

doi:10.3969/j.issn.1672-5069.2022.03.002

实用肝脏病杂志 ›› 2022, Vol. 25 ›› Issue (3): 309-313.doi: 10.3969/j.issn.1672-5069.2022.03.002

NASH患者肝巨噬细胞在肝纤维化形成过程中的作用及其临床转化研究进展^*

韩冰, 涂传涛

200434上海市同济大学附属上海市第四人民医院消化内科

收稿日期:2022-03-15 出版日期:2022-05-10 发布日期:2022-05-17
通讯作者: 涂传涛,E-mail:tuchuantao@hotmail.com
作者简介:韩冰,女,38岁,医学硕士,主治医师。主要从事慢性肝病基础与临床研究。E-mail:sh_hanbing@sina.com
基金资助:
^*国家自然科学基金资助项目(编号:81970531)

Role of intrahepatic macrophages in the development of liver fibrosis in patients with NASH and the clinical transformation perspective

HanBing, Tu Chuantao

Department of Gastroenterology, Fourth People's Hospital, School of Medicine, Tongji University, Shanghai 200434, China

Received:2022-03-15 Online:2022-05-10 Published:2022-05-17

摘要/Abstract

关键词: 非酒精性脂肪性肝炎, 肝纤维化, 肝巨噬细胞

Key words: Nonalcoholicsteatohepatitis, Hepaticfibrosis, Hepaticmacrophages

韩冰, 涂传涛. NASH患者肝巨噬细胞在肝纤维化形成过程中的作用及其临床转化研究进展^*[J]. 实用肝脏病杂志, 2022, 25(3): 309-313.

HanBing, Tu Chuantao. Role of intrahepatic macrophages in the development of liver fibrosis in patients with NASH and the clinical transformation perspective[J]. Journal of Practical Hepatology, 2022, 25(3): 309-313.

参考文献

[1] Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet,2021,397(10290):2212-2224.
[2] Friedman SL, Neuschwander-Tetri BA, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies. Nat Med,2018,24(7):908-922.
[3] Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell,2021,184(10):2537-2564.
[4] Schwabe RF, Tabas I, Pajvani UB. Mechanisms offibrosis development in nonalcoholic steatohepatitis. Gastroenterology,2020,158(7):1913-1928.
[5] Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci,2019,76(1):99-128.
[6] Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism,2016,65(8):1038-1048.
[7] Alzaid F, Lagadec F, Albuquerque M, et al. IRF5 governs liver macrophage activation that promotes hepatic fibrosis in mice and humans. JCI Insight,2016,1(20):e88689.
[8] Kondylis V, Pasparakis M. RIP kinases in liver cell death, inflammation and cancer. Trends Mol Med,2019,25(1):47-63.
[9] Gaul S, Leszczynska A, Alegre F, et al. Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis. J Hepatol,2021,74(1):156-167.
[10] Kazankov K, Jørgensen SMD, Thomsen KL, et al. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol,2019,16(3):145-159.
[11] Huby T, Gautier EL. Immune cell-mediated features of non-alcoholic steatohepatitis. Nat Rev Immunol,2021:1-15.
[12] Tacke F. Targeting hepatic macrophages to treat liver diseases. J Hepatol,2017,66(6):1300-1312.
[13] Yona S, Kim KW, Wolf Y, et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity,2013,38(1):79-91.
[14] Guilliams M, Bonnardel J, Haest B, et al. Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches. Cell,2022,185(2):379-396,e38.
[15] Tran S, Baba I, Poupel L, et al. Impaired Kupffercell self-renewal alters the liverresponse to lipid overload during non-alcoholic steatohepatitis. Immunity,2020,53(3):627-640.
[16] Devisscher L, Scott CL, Lefere S, et al. Non-alcoholic steatohepatitis induces transient changes within the liver macrophage pool. Cell Immunol,2017,322:74-83.
[17] Seidman JS, Troutman TD, Sakai M, et al. Niche-specific reprogramming of epigenetic landscapes drives myeloid cell diversity in nonalcoholic steatohepatitis. Immunity,2020,52(6):1057-1074.
[18] Daemen S, GainullinaA, Kalugotla G, et al. Dynamic shifts in the composition of resident and recruited macrophages influence tissue remodeling in NASH. Cell Rep,2021,34(2):108626.
[19] Remmerie A, MartensL, Thoné T, et al. Osteopontinexpression identifies a subset of recruited macrophages distinct from Kupffercells in the fatty liver. Immunity,2020,53(3):641-657.
[20] De Muynck K, Vanderborght B, Van Vlierberghe H, et al. The gut-liver axis in chronic liver disease: A macrophage perspective. Cells,2021,10(11):2959.
[21] Cai B, Dongiovanni P, Corey KE, et al. Macrophage MerTKpromotes liver fibrosis in nonalcoholic steatohepatitis. Cell Metab,2020,31(2):406-421.
[22] Hong CH, Ko MS, Kim JH, et al. Sphingosine 1-phosphate receptor 4 promotes nonalcoholic steatohepatitis by activating NLRP3 inflammasome. Cell MolGastroenterol Hepatol,2022,13(3):925-947.
[23] Schuster S, Cabrera D, Arrese M, et al. Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol,2018,15(6):349-364.
[24] Musso G, Cassader M,Paschetta E, et al. Bioactive lipid species and metabolic pathways in progression and resolution of nonalcoholic steatohepatitis. Gastroenterology,2018,155(2):282-302.
[25] Yao Q, Li S, Li X, et al. Myricetinmodulates macrophage polarization and mitigates liver inflammation and fibrosis in a murine model of nonalcoholic steatohepatitis. Front Med (Lausanne),2020,7:71.
[26] Spite M. Resolving inflammation in nonalcoholic steatohepatitis. J Clin Invest,2019,129(4):1524-1526.

NASH患者肝巨噬细胞在肝纤维化形成过程中的作用及其临床转化研究进展^*

Role of intrahepatic macrophages in the development of liver fibrosis in patients with NASH and the clinical transformation perspective

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	郭悦承, 陆伦根. 肝纤维化临床诊断与治疗研究进展[J]. 实用肝脏病杂志, 2022, 25(3): 305-308.
[2]	严兆兰, 祖红梅, 蔡长霞, 魏巍. 血清低水平丙氨酸氨基转移酶的HBV感染者临床特征分析^*[J]. 实用肝脏病杂志, 2022, 25(3): 343-346.
[3]	李春花, 李忠新, 张春雷, 曾学辉, 陈甜甜, 宋林立. 不同肝纤维化程度的慢性乙型肝炎患者血清FGF-21、PDGF-BB和FBRS水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2022, 25(3): 347-350.
[4]	周兴, 易怀红, 宋廉. 超声弹性成像声触诊组织成像量化指标评估肝血吸虫病患者肝纤维化价值临床研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 399-402.
[5]	杨艳, 刘婷, 戴琳, 努丽曼姑·麦麦提, 刘环. 声触诊弹性成像检测肝脾硬度诊断慢性乙型肝炎患者肝纤维化效能分析^*[J]. 实用肝脏病杂志, 2022, 25(2): 183-186.
[6]	黄平, 曾霞, 张亚萍, 毛加丽. 肝静脉波形分型联合肝脏超声半定量评分对慢性乙型肝炎患者肝纤维化程度评估价值研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 187-190.
[7]	王琳, 林雪松, 丁楠. 非酒精性单纯性脂肪肝与非酒精性脂肪性肝炎患者血清脂质组学比较^*[J]. 实用肝脏病杂志, 2022, 25(2): 215-218.
[8]	郑淑颖, 郭欢欢, 程长浩, 冯珍珍. 索非布韦联合雷迪帕韦治疗慢性丙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(1): 26-29.
[9]	闻啟富, 马利军, 王晓亮. 非酒精性脂肪性肝炎患者血清CK18和FGF-21水平变化及其临床意义探讨[J]. 实用肝脏病杂志, 2021, 24(6): 835-838.
[10]	王子璇, 王梦雨, 李经纬, 杨蕊旭, 曾静, 潘勤, 范建高. 门冬氨酸鸟氨酸对非酒精性脂肪性肝炎合并肌少症性肥胖小鼠的保护作用^*[J]. 实用肝脏病杂志, 2021, 24(5): 657-660.
[11]	李妍, 陆伦根, 蔡晓波. HIF-1α对非酒精性脂肪性肝病小鼠肝组织的影响^*[J]. 实用肝脏病杂志, 2021, 24(5): 665-668.
[12]	王利公, 赵珊, 白凯, 张宁, 张楠. 慢性乙型肝炎患者血清α1酸性糖蛋白、α1-抗胰蛋白酶和触珠蛋白变化及其临床意义探讨[J]. 实用肝脏病杂志, 2021, 24(5): 673-676.
[13]	杨永汉, 路萍, 孟庆宁, 张枫婕. 增强MRI T1 mapping定量评估慢性乙型肝炎患者肝纤维化程度效能分析[J]. 实用肝脏病杂志, 2021, 24(5): 685-688.
[14]	杨艳秋, 程颢, 冯敏. 肝脏剪切波弹性成像对慢性乙型肝炎患者肝纤维化的评估价值^*[J]. 实用肝脏病杂志, 2021, 24(4): 480-483.
[15]	孙海荣, 冯伟广, 周冰清, 刘慧敏, 蒋蓓莉. 不同血清ALT水平的乙型肝炎病毒感染者肝纤维化指标变化[J]. 实用肝脏病杂志, 2021, 24(4): 488-491.